Temenos and Mastercard join forces to expand cross-border payment capabilities through Mastercard Move
June 04, 2024 09:00 ET
|
Temenos
NEW YORK and GENEVA, June 04, 2024 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN) today announced a collaboration with Mastercard, a leading global technology company in the payments industry, to...
WISe.ART Partners with Sustainable Fashion Innovation Society on Upcoming Phygital Sustainability Expo
June 03, 2024 13:03 ET
|
Wisekey International Holding Ltd.
Announcement on the Nasdaq Tower in New York City can be viewed at https://youtu.be/28nV8L_TXaw?si=Fb1_EBN7LQcLGfFb Livestreams of the Expo’s conferences...
New data with daridorexant to be presented at SLEEP 2024
June 03, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults with insomnia,...
New data with daridorexant to be presented at SLEEP 2024
June 03, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults with insomnia,...
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
June 01, 2024 08:00 ET
|
Molecular Partners
Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironmentFavorable and manageable safety profile observed at all tested dose levelsWeekly...
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
May 31, 2024 08:00 ET
|
Novartis Pharma AG
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs....
Kuntarahoitus laskee liikkeeseen 11 miljoonan euron joukkovelkakirjalainan osana joukkovelkakirjalainaohjelmaa
May 31, 2024 03:00 ET
|
Kuntarahoitus Oyj
Kuntarahoitus OyjPörssitiedote31.5.2024 klo 10.00 Kuntarahoitus laskee liikkeeseen 11 miljoonan euron joukkovelkakirjalainan osana joukkovelkakirjalainaohjelmaa Kuntarahoitus Oyj laskee...
Municipality Finance issues EUR 11 million notes under its MTN programme
May 31, 2024 03:00 ET
|
Municipality Finance Plc
Municipality Finance PlcStock exchange release 31 May 2024 at 10:00 am (EEST) Municipality Finance issues EUR 11 million notes under its MTN programme Municipality Finance Plc issues...
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
May 31, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented by Prof....
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
May 31, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented by Prof....